ClinicalTrials.gg
RecruitingNCT06017817Updated Aug 7, 2026

Antibacterial Photodynamic Therapy in the Management of Peri-implantitis

An interventional study of Lumoral Treatment and Standard oral hygiene instructions in Peri-Implantitis and Plaque, Dental, sponsored by Koite Health Oy. Recruiting at 1 site in Sweden. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-08-07.

Sponsored by Koite Health Oy · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Peri-Implantitis with a site in Sweden — 5 open to participants now, 6 under way, none of them phase 3. Peri-Implantitis · Sweden.

Planned enrollment
4th of 12
80 · median 74
Started
2024
with 1 other
No phase
8 of 21
2 open now
Registered
17th of 21
by date
Lead sponsor
1 of 21
Koite Health Oy

Among the 21 studies in Peri-Implantitis with a site in Sweden, this one is the 4th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2024, is one of 8 with no phase, and was the 17th registered.

Peri-Implantitis

324 studies on the registry are indexed under Peri-Implantitis; 89 are open to participants now.

Browse Peri-Implantitis studies →

Open to participants now

5 of the 21 studies in Peri-Implantitis with a site in Sweden are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 50 Peri-Implantitis studies recruiting now, 28 (56%) set no upper age limit and 9 (18%) stop at 75 or younger; 7 take children under 18; 26 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Peri-Implantitis with a site in Sweden, or all of them as a file.
02

Study summary

This early-stage study is designed to determine the efficacy of the Lumoral method in periimplantitis. Improved supragingival plaque control can help to also sustain subgingival plaque management in the long term. In addition, the device might have a photobiomodulation effect on periodontal tissues, thus impacting osseointegration.

Read the detailed description

Clinical signs of inflammation in peri-implantitis include bleeding on probing, suppuration, increased probing depth, and radiographic signs of bone loss. Currently, the best treatment options for peri-implantitis include non-surgical methods of biofilm removal in the supra-mucosal area around implants, and comprehensive guidance on self-performed infection control procedures. With more advanced peri-implantitis, anti-infective surgical treatment protocol would be needed.

Matrix metalloproteinase 8 (MMP-8) has been found to be elevated in association with oral infections, such as periodontitis and peri-implantitis. The level of active MMP-8 (aMMP-8) can detect to determine tissue health and to assess inflammation, and can easily be measured during a regular dental appointment with a chairside test.

The Lumoral Treatment is a CE-marked medical device developed to provide a potent, targeted antibacterial action on dental plaque in a home environment. The method mechanism of action is antibacterial photodynamic therapy (aPDT). The method is used by swishing a mouth rinse, which has a strong adherence to dental plaque. The plaque-adhered photoactive mouth rinse can be activated by a simple-to-use light applicator. Preliminary results have shown a promising anti-inflammatory response in addition to plaque reduction.

03

Conditions studied

  • Peri-Implantitis
  • Plaque, Dental

Keywords

  • Lumoral
  • Lumorinse
  • Antibacterial photodynamic therapy (aBPT)
  • aMMP-8
  • Plaque control
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • PPD ≥6 mm and marginal bone loss >3 mm
  • Dental implants collected and clinically characterized according to Lähteenmäki et al. CEDR-22
  • Agreement to participate in the study and to sign a written consent form
  • Able to co-operate with the treatment protocol and avoid any other oral hygiene measures outside of the study protocol

Exclusion criteria

Exclusion Criteria:

  • Presence of any physical limitation or restriction that might restrict Lumoral use
  • Unwilling to participate in the study
  • Pregnancy or lactation
  • Active smoking
  • Medicated diabetes mellitus (DM)
  • Any systemic disease (e.g., wound healing dysfunctions) that could alter the progression of peri-implantitis
  • Use of antibiotics and doxycycline, chlorhexidine, and bisphosphonates, within 4 weeks week prior to study participation
  • Peri-implant and periodontal treatment within 3 months prior to study participation
  • Removable major prosthesis or major orthodontic appliance
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Non-surgical treatment, Study group (NST-1)

    Lumoral Treatment; Standard, non-surgical anti-infective treatment by scaling and root planing (SRP); and Standard oral hygiene instructions for electric toothbrushing, interdental brush, and dental floss use.

    Device: Lumoral Treatment · Procedure: Standard oral hygiene instructions · Procedure: Scaling and root planing (SRP

  • Active comparator
    Non-surgical treatment, Control group (NST-2)

    Standard, non-surgical anti-infective treatment by scaling and root planing (SRP); and Standard oral hygiene instructions for electric toothbrushing, interdental brush, and dental floss use.

    Procedure: Standard oral hygiene instructions · Procedure: Scaling and root planing (SRP

  • Experimental
    Surgical treatment, Study group (ST-1)

    Lumoral Treatment; Surgical anti-infective peri-implantitis treatment; and Standard oral hygiene instructions for electric toothbrushing, interdental brush, and dental floss use.

    Device: Lumoral Treatment · Procedure: Standard oral hygiene instructions · Procedure: surgical anti-infective peri-implantitis treatment

  • Active comparator
    Surgical treatment, Control group (ST-2)

    Surgical anti-infective peri-implantitis treatment; and Standard oral hygiene instructions for electric toothbrushing, interdental brush, and dental floss use.

    Procedure: Standard oral hygiene instructions · Procedure: surgical anti-infective peri-implantitis treatment

Interventions

  • DeviceLumoral Treatment

    Anti-infective photodynamic therapy for plaque-induced oral conditions

  • ProcedureStandard oral hygiene instructions

    Standard oral hygiene instructions for electric toothbrushing, interdental brush, and dental floss use

  • ProcedureScaling and root planing (SRP

    non-surgical anti-infective treatment by scaling and root planing

  • Proceduresurgical anti-infective peri-implantitis treatment

    surgical anti-infective peri-implantitis treatment

06

What researchers measure

Primary outcomes

  1. Bleeding on probing (BOP)

    Change in the inflammatory parameter BOP. A full-mouth assessment at six sites per tooth: * Gingival bleeding is considered as positive if bleeding occurs within 15 seconds after gentle probing with a probe at the sulcus * Dichotomous scoring to each site of the tooth as bleeding "1 present" and "0 absent" * BOP reported as the percentage (%) of sites with positive findings * Calculation formula: number of bleeding sites/ 6 times number of teeth

    Time frame: 6 months

Secondary outcomes

  1. Active matrix metalloproteinase 8 (aMMP-8)

    The oral rinse fluid sample collection and the aMMP-8 marker analysis will be performed using Periosafe test (Dentognostics GmbH) according to the manufacturer's instructions.

    Time frame: 6 months

  2. Inflammatory marker total MMP-8 analysis

    Measurement of pro and active MMP-8. Units: ng/ml.

    Time frame: 6 months

  3. Inflammatory marker total MMP-9 analysis

    Measurement of pro and active MMP-9. Units: ng/ml.

    Time frame: 6 months

  4. Inflammatory marker total MMP-2 analysis

    Measurement of pro and active MMP-2. Units: ng/ml.

    Time frame: 6 months

  5. Inflammatory marker total TIMP analysis

    Units: ng/ml.

    Time frame: 6 months

  6. Interleukins analysis

    Units: pg/ml.

    Time frame: 6 months

  7. Total calprotectin analysis

    Salivary calprotectin. Units: microgram/ml.

    Time frame: 6 months

  8. Peridontal Pocket Depth (PPD)

    A full-mouth assessment, measured at six sites per tooth. Assessed from the base of the pocket to the gingival margin (mm)

    Time frame: 6 months

  9. Visual Plaque Index( VPI)

    Assessment of six index teeth, measured at four sites per tooth * Dichotomous scoring to each site of the tooth as plaque "1 present" and "0 absent" * VPI reported as the percentage (%) of sites with plaque * Calculation formula: number of sites with plaque/ 4 times number of teeth

    Time frame: 6 months

  10. Clinical Attachment Level (CAL)

    A full-mouth assessment, measured at six sites per tooth \- Assessed as the distance from the cementoenamel junction (CEJ) to the bottom of the periodontal pocket (mm) The measurements to calculate CAL: * distance from the gingival margin to the CEJ and PPD * in recession: PPD + gingival margin to the CEJ * in tissue overgrowth: PPD - gingival margin to the CEJ

    Time frame: 6 months

  11. Bacterial flora

    Quantification of periodontopathic bacteria by 16S rRNA sequencing analysis \- Microbiological samples can be collected using Iso Taper Paper Points, size-20 (VDW GmbH) from selected gingival/periodontal pockets with maximum initial probing depth. The paper points can be placed into sterile, small-aliquot containers, and immediately stored at -20°C until analysis

    Time frame: 6 Months

  12. Adverse events

    Any suspicion of an adverse event related to the investigational device, the treatment method, or the study protocol.

    Time frame: 6 months

  13. OHIP-14 questionnaire

    \- Measures people's perception of the social impact of oral disorders on their well-being. Fourteen items of OHIP are divided into seven dimensions: functional limitation, physical discomfort, psychological discomfort, physical disability, psychological disability, social disability, and handicaps. (Slade GD 1997). Responses are made on a 5-point scale (from 0 = never, to 4 = very often).

    Time frame: 6 months

Other outcomes

  1. Mobility assessment

    Manual assessment of the template movement, mobility testing sideways, and up and down \- Scoring in numbers 0 - 3

    Time frame: 6 months

  2. Suppuration index

    \- Visual assessment of the amount of pus, scoring: 0: No suppuration or exudate present 1. Minimal suppuration or exudate present 2. Moderate suppuration or exudate present 3. Severe suppuration or exudate present

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
  • Södertandläkarna AB
    Stockholm, 11622, Sweden
    Recruiting
    • Nilminie Rathnayake, Periodontist · Contact
08

References and documents

Publications

  • Berglundh T, Jepsen S, Stadlinger B, Terheyden H. Peri-implantitis and its prevention. Clin Oral Implants Res. 2019 Feb;30(2):150-155. doi: 10.1111/clr.13401. Epub 2019 Feb 3. PubMed 30636066 ↗
  • Jepsen S, Berglundh T, Genco R, Aass AM, Demirel K, Derks J, Figuero E, Giovannoli JL, Goldstein M, Lambert F, Ortiz-Vigon A, Polyzois I, Salvi GE, Schwarz F, Serino G, Tomasi C, Zitzmann NU. Primary prevention of peri-implantitis: managing peri-implant mucositis. J Clin Periodontol. 2015 Apr;42 Suppl 16:S152-7. doi: 10.1111/jcpe.12369. PubMed 25626479 ↗
  • Kassebaum NJ, Bernabe E, Dahiya M, Bhandari B, Murray CJ, Marcenes W. Global burden of severe periodontitis in 1990-2010: a systematic review and meta-regression. J Dent Res. 2014 Nov;93(11):1045-53. doi: 10.1177/0022034514552491. Epub 2014 Sep 26. PubMed 25261053 ↗
  • Kassebaum NJ, Smith AGC, Bernabe E, Fleming TD, Reynolds AE, Vos T, Murray CJL, Marcenes W; GBD 2015 Oral Health Collaborators. Global, Regional, and National Prevalence, Incidence, and Disability-Adjusted Life Years for Oral Conditions for 195 Countries, 1990-2015: A Systematic Analysis for the Global Burden of Diseases, Injuries, and Risk Factors. J Dent Res. 2017 Apr;96(4):380-387. doi: 10.1177/0022034517693566. PubMed 28792274 ↗
  • Lang NP, Suvan JE, Tonetti MS. Risk factor assessment tools for the prevention of periodontitis progression a systematic review. J Clin Periodontol. 2015 Apr;42 Suppl 16:S59-70. doi: 10.1111/jcpe.12350. PubMed 25496279 ↗
  • Lahteenmaki H, Patila T, Raisanen IT, Kankuri E, Tervahartiala T, Sorsa T. Repeated Home-Applied Dual-Light Antibacterial Photodynamic Therapy Can Reduce Plaque Burden, Inflammation, and aMMP-8 in Peri-Implant Disease-A Pilot Study. Curr Issues Mol Biol. 2022 Mar 8;44(3):1273-1283. doi: 10.3390/cimb44030085. PubMed 35723308 ↗
  • Nikinmaa S, Moilanen N, Sorsa T, Rantala J, Alapulli H, Kotiranta A, Auvinen P, Kankuri E, Meurman JH, Patila T. Indocyanine Green-Assisted and LED-Light-Activated Antibacterial Photodynamic Therapy Reduces Dental Plaque. Dent J (Basel). 2021 May 3;9(5):52. doi: 10.3390/dj9050052. PubMed 34063662 ↗
  • Slade GD. Derivation and validation of a short-form oral health impact profile. Community Dent Oral Epidemiol. 1997 Aug;25(4):284-90. doi: 10.1111/j.1600-0528.1997.tb00941.x. PubMed 9332805 ↗

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Dec 2026, 31 months after the start.

Of 128 interventional studies with no phase under Peri-Implantitis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's planned 31 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2023
First posted
Aug 30, 2023
StartActual
May 13, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Aug 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06017817
Lead sponsor
Koite Health Oy
Collaborators
University of Helsinki, Södertandläkarna
Responsible party
Sponsor
First posted
Aug 30, 2023
Start date
May 13, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Aug 7, 2026

Study contacts

Mikko Kylmänen
Contact
mikko.kylmanen@koitehealth.com
+358407245934
Nilminie Rathnayake, Assoc Prof
principal investigator · University of Helsinki

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion